BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. Source
No articles found.
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing an...
Soligenix, Inc. is a late-stage biopharmaceutic...
CytoDyn is a publicly traded late stage biotechnology company developing innovativ...
CytoDyn is a publicly traded late stage biotech...
Lonza is an integrated solutions provider that creates value along the Healthcare ...
Lonza is an integrated solutions provider that ...
Forward Pharma A/S is a Danish biopharmaceutical company that commenced developmen...
Forward Pharma A/S is a Danish biopharmaceutica...
The mission of Cassava Sciences is to detect and treat neurodegenerative diseases,...
The mission of Cassava Sciences is to detect an...
Prothena Corporation plc (Nasdaq: PRTA) is a clinical-stage neuroscience company f...
Prothena Corporation plc (Nasdaq: PRTA) is a cl...
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapie...
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)...
Join the National Investor Network and get the latest information with your interests in mind.